Celsion Corporation (CLSN)

NASDAQ: CLSN · IEX Real-Time Price · USD
0.390
-0.044 (-10.07%)
At close: Jan 21, 2022 4:00 PM
0.400
0.010 (2.485%)
After-hours:Jan 21, 2022 7:58 PM EST
Market Cap33.78M
Revenue (ttm)500,000
Net Income (ttm)-19.56M
Shares Out86.56M
EPS (ttm)-0.28
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume847,895
Open0.418
Previous Close0.434
Day's Range0.385 - 0.440
52-Week Range0.386 - 3.480
Beta1.90
AnalystsStrong Buy
Price Target3.25 (+732.7%)
Earnings Daten/a

About CLSN

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers. Celsion Corporation was founded in 1982 and i...

IndustryBiotechnology
IPO DateMar 5, 1985
CEOMichael Tardugno
Employees27
Stock ExchangeNASDAQ
Ticker SymbolCLSN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for Celsion stock is "Strong Buy" and the 12-month stock price forecast is 3.25.

Price Target
$3.25
(732.69% upside)
Analyst Consensus: Strong Buy

News

Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred ...

LAWRENCEVILLE, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today ann...

1 week ago - GlobeNewsWire

Celsion Corporation Invited to Present Poster at Cytokine-Based Cancer Immunotherapies Summit

Celsion Corporation 's GEN-1 IL-12 Program in Ad vanced Ovarian Cancer to be Featured in Poster Presentation

1 month ago - GlobeNewsWire

Celsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update

Balance Sheet Supports Focus o n Immuno-Oncology and Next-Generation Vaccine Initiative

2 months ago - GlobeNewsWire

Celsion Corporation to Hold Third Quarter 2021 Financial Results and Business Update Conference Call on Monday, Novem...

LAWRENCEVILLE, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announce...

2 months ago - GlobeNewsWire

Celsion Provides Update on its Application to Sell $1.5 Million of New Jersey Net Operating Losses

Application A pproval Will Further Extend Current Operating Runway to Over Three Years

2 months ago - GlobeNewsWire

Celsion Corporation's GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapies Summit

Chief Science Officer Dr. Khursheed Anwer to also Participate in Two Panel Discussions

2 months ago - GlobeNewsWire

Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress

Chief Science Officer Dr. Khursheed Anwer to D eliver V irtual P resentation Monday, October 18 at 7:30 a.m. Eastern Time

3 months ago - GlobeNewsWire

Celsion Corporation Announces Oral Presentation at International Vaccines Congress

Chief Science Officer Dr. Khursheed Anwer to D eliver V irtual P resentation on Celsion's O ngoing W ork with DNA-based V accines

3 months ago - GlobeNewsWire

Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® Drug Development in Advanced...

Investigator-Sponsored Research with ThermoDox ® Continues in Multiple Indications

3 months ago - GlobeNewsWire

Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities

LAWRENCEVILLE, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces...

3 months ago - GlobeNewsWire

Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion's DNA-based Vaccine

E xpands GEN-1 P rogram C ollaboration to Add C linical and C ommercial B atches of I nvestigational V accine

4 months ago - GlobeNewsWire

Hot Penny Stocks to Add to Your September Watchlist

Why investors are watching these 3 penny stocks right now The post Hot Penny Stocks to Add to Your September Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols:ADXSTELL
4 months ago - PennyStocks

Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies

Celsion (CLSN) announces data from pre-clinical studies for its investigational vaccine platform as a potential treatment for COVID-19.

4 months ago - Zacks Investment Research

Hot Penny Stocks to Watch Right Now, Have You Heard of These 3?

Are these penny stocks on your watchlist in August 2021? The post Hot Penny Stocks to Watch Right Now, Have You Heard of These 3?

Other symbols:DAREMMAT
5 months ago - PennyStocks

Penny Stocks to Buy This Week? 4 You Need to Know About

What you need to know about these 4 penny stocks this week? The post Penny Stocks to Buy This Week?

Other symbols:CEINAOVSOLO
5 months ago - PennyStocks

Celsion Corporation to Hold Second Quarter 2021 Financial Results and Business Update Conference Call on Thursday, Au...

LAWRENCEVILLE, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced...

5 months ago - GlobeNewsWire

Results of Celsion's OVATION 1 Study with GEN-1 in Patients with Advanced Ovarian Cancer Published in the Journal of ...

Data show d ose - dependent suppression of immun e- suppressive agents

5 months ago - GlobeNewsWire

Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of th...

OVATION 2 Study is 50% Enrolled; Excellent R0 Surgical Resection Noted

6 months ago - GlobeNewsWire

3 Biopharma Penny Stocks That Could be Millionaire Makers

These three biotech penny stocks all have developed drugs that have shown strong indications of success. The post 3 Biopharma Penny Stocks That Could be Millionaire Makers appeared first on InvestorPlace.

Other symbols:VTVTZSAN
6 months ago - InvestorPlace

Celsion GmbH Announces Commencement of Enrollment in Oxford University's Phase 1 Study with ThermoDox® and Focused Ul...

LAWRENCEVILLE, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), Celsion GmbH, a wholly owned subsidiary of Celsion Corporation, a clinical-stage biotechnology company, announc...

6 months ago - GlobeNewsWire

Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®

Celsion GmbH will manage current and future cancer studies with Thermo D ox ®

7 months ago - GlobeNewsWire

Celsion Corporation Enters into $10 Million Strategic Loan Facility with Silicon Valley Bank

Improvement to the Balance Sheet Leverages Strong Equity Structure

7 months ago - GlobeNewsWire

Do Options Traders Know Something About Celsion (CLSN) Stock We Don't?

Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Celsion Appoints Christine A. Pellizzari to its Board of Directors

Brings extensive biopharmaceutical legal background to the Board

7 months ago - GlobeNewsWire

Celsion Corporation Appoints Dr. Stacy R. Lindborg to its Board of Directors

25-year pharmaceutical industry executive brings broad drug development perspective

7 months ago - GlobeNewsWire